[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07473128":3,"trial-entities:NCT07473128":96,"trial-summary:NCT07473128":100},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":40,"secondary_outcomes":45,"sex":56,"minimum_age":57,"maximum_age":17,"healthy_volunteers":58,"eligibility_criteria":59,"std_ages":71,"locations":74,"central_contacts":90,"overall_officials":93,"references":94,"see_also_links":95},"NCT07473128","LS-SCLC-01","Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer","RECRUITING","2027-06","2026-06","2026-06-17","2026-06-30","Pharmacosmos A\u002FS","INDUSTRY",true,"The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:\n\nDoes trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?\n\nParticipants will be randomised to receive either trilaciclib or placebo.",null,[19],"Limited Stage Small Cell Lung Cancer",[],"INTERVENTIONAL","SUPPORTIVE_CARE",[24],"PHASE3",{"count":26,"type":27},120,"ESTIMATED",[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33},"DRUG","Trilaciclib","Intravenous infusion",[31],{"type":30,"name":35,"description":32,"armGroupLabels":36,"otherNames":38},"Saline (0.9% NaCl)",[37],"Placebo",[39],"dextrose",[41],{"measure":42,"description":43,"timeFrame":44},"To Compare trilaciclib to placebo on prevention of myelosuppression","Duration and occurrence of severe neutropenia","From enrollment and 4 months after",[46,48,50,52,54],{"measure":47,"timeFrame":44},"Number of all-cause chemotherapy dose reductions",{"measure":49,"timeFrame":44},"Occurrence of granulocyte colony-stimulating factor (G-CSF) administration",{"measure":51,"timeFrame":44},"Number of hospitalizations due to myelosuppression or sepsis",{"measure":53,"timeFrame":44},"Number of febrile neutropenia",{"measure":55,"timeFrame":44},"Occurrence of red blood cell (RBC) transfusions","ALL","18 Years",false,{"inclusion":60,"exclusion":65,"raw_text":70},[61,62,63,64],"Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer","Complete recovery from prior anti-tumor surgical procedures","Measurable and evaluable disease through tumor assessment","Willingness to participate and sign informed consent form",[66,67,68,69],"Extensive Stage Small Cell Lung Cancer","Active cardiovascular disease","Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations","Pregnant or nursing women","Inclusion Criteria:\n\n* Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer\n* Complete recovery from prior anti-tumor surgical procedures\n* Measurable and evaluable disease through tumor assessment\n* Willingness to participate and sign informed consent form\n\nExclusion Criteria:\n\n* Extensive Stage Small Cell Lung Cancer\n* Active cardiovascular disease\n* Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations\n* Pregnant or nursing women",[72,73],"ADULT","OLDER_ADULT",[75],{"facility":76,"status":8,"city":77,"state":78,"zip":79,"country":80,"contacts":81,"geoPoint":87},"Pharmacosmos Investigational Site","Oakland","California","48073","United States",[82],{"name":83,"role":84,"phone":85,"email":86},"Pharmacosmos A\u002FS Clinical and non-clinical research","CONTACT","455-948-5959","info@pharmacosmos.com",{"lat":88,"lon":89},37.80437,-122.2708,[91],{"name":83,"role":84,"phone":92,"email":86},"+4559485959",[],[],[],{"nct_id":4,"conditions":97,"biomarkers":99},[98],"Lung Small Cell Carcinoma",[],{"nct_id":4,"found":58,"summary":17,"prompt_version":17}]